The Muscular Dystrophy Association recently awarded an MDA human clinical trial grant for the development of a critical biomarker for Charcot-Marie-Tooth disease (CMT) to Mary M. Reilly, professor of clinical neurology and consultant neurologist, UCL Institute of Neurology and National Hospital for Neurology and Neurosurgery, London. The investment, totaling $1 million over three years, will . . .
MDA has announced the award of 13 new grants totaling $2.6 million as part of its continued commitment to finding treatments and cures for the diseases in its program. Each of the 13 new grants funds a project that aims to increase our understanding of the causes or underlying mechanisms of neuromuscular disease or potential . . .
Since 1986, when MDA-funded researchers identified the gene that, when flawed, leads to Duchenne muscular dystrophy (DMD), scientists have been actively pursuing treatments and cures. In the past 12 months, MDA has awarded research grants to the following individuals who are building on the strong foundation of previous research and discovery to better understand — and someday cure — the diseases.
Angela Lek, a postdoctoral research fellow at Boston Children sHospital, was awarded an MDA development grant totaling $180,000 over three years to use cutting-edge techniques and a novel approach to search for drug targets in FSHD.